Stemline Therapeutics (STML)

Latest Trade: $14.67

IPO News

Weekly Recap: Most January pricings since 2006, Zoetis surges in debut 2/1/13
Biotech Stemline Therapeutics prices upsized IPO at $10, the low end of the range 1/28/13
5 US IPOs planned for the week of Jan 28 1/28/13
Stemline Therapeutics increases proposed IPO deal size 1/9/13
Stemline Therapeutics slashes deal size in half 10/22/12
Stemline Therapeutics postpones IPO 8/7/12
6 US IPOs planned for the week of Aug 6 8/6/12
4 US IPOs planned for the week of Jul 30 7/30/12
Stemline Therapeutics set terms for $42 million US IPO 7/20/12
Biotech Stemline Therapeutics files for $50 million US IPO 4/2/12

Performance History

Interested in IPO Investing?

First Day Return
11.8000

18.0%
Aftermarket Return
11.8000

24.3%
Return from IPO
10.0000

46.7%

IPO Date
01/28/13
Offer Price
$10.00
Offer Shares
3.3 mm
Lead Manager(s)
Aegis Capital Corp.
Co Manager(s)
Feltl and Company

All Underwriters

Business

Business
Biotech developing treatments that target cancer stem cells and tumor bulk.
Industry
Health-Drugs
Employees
8
Founded
2003

STML Daily

Chart

Corporate Data

Company Address
750 Lexington Avenue, Sixth Floor
New York, NY
Phone Number
(646) 502-2310
Web Address
www.stemline.com